Patents by Inventor Pierre-Francois Berne

Pierre-Francois Berne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220340682
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also disclosers immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 25, 2022
    Publication date: October 27, 2022
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 11332542
    Abstract: Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: May 17, 2022
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20200102401
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: September 3, 2019
    Publication date: April 2, 2020
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 10457739
    Abstract: Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 29, 2019
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20180022817
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 25, 2018
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 9617345
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 11, 2017
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20160108131
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: May 19, 2015
    Publication date: April 21, 2016
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Publication number: 20120270250
    Abstract: The present invention relates to a test system for measuring MEST activity, a method for screening for a ligand for MEST and the use of the test system for the identification of a MEST ligand, particularly a MEST inhibitor.
    Type: Application
    Filed: June 25, 2010
    Publication date: October 25, 2012
    Applicant: SANOFI
    Inventors: Günter Müller, Christian Jung, Qing Zhou-Liu, Pierre-Francois Berne, Cecile Capdevila
  • Publication number: 20110150903
    Abstract: The present invention relates to FGF-R4 receptor-specific antagonist molecules enabling the inhibition of the activity of said receptor. Said antagonists are, particularly, FGF-R4-specific antibodies enabling the inhibition of the activity of said receptor. The present invention also relates to the therapeutic use of said antibodies, particularly in the field of angiogenesis and in the treatment of certain types of cancer.
    Type: Application
    Filed: July 7, 2009
    Publication date: June 23, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Nicolas Baurin, Pierre-Francois Berne, Francis Blanche, Francoise Bono, Beatrice Cameron, Tarik Dabdoubi, Corentin Herbert, Vincent Mikol, Elisabeth Remy